Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) was $34.28 for the day, up 2.36% from the previous closing price of $33.49. In other words, the price has increased by $2.36 from its previous closing price. On the day, 0.55 million shares were traded. KNSA stock price reached its highest trading level at $34.505 during the session, while it also had its lowest trading level at $33.54.
Ratios:
Our analysis of KNSA’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.21. For the most recent quarter (mrq), Quick Ratio is recorded 3.16 and its Current Ratio is at 3.57. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $40.
On September 13, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $40. On May 03, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $34.Wells Fargo initiated its Overweight rating on May 03, 2024, with a $34 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 ’25 when Tessari Eben sold 16,200 shares for $33.77 per share. The transaction valued at 547,141 led to the insider holds 40,215 shares of the business.
Tessari Eben bought 16,200 shares of KNSA for $547,070 on Aug 18 ’25. On Aug 14 ’25, another insider, Malley Thomas, who serves as the Director of the company, sold 78,233 shares for $33.09 each. As a result, the insider received 2,588,730 and left with 12,546 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KNSA now has a Market Capitalization of 2540411648 and an Enterprise Value of 2242393856. As of this moment, Kiniksa’s Price-to-Earnings (P/E) ratio for their current fiscal year is 834.06, and their Forward P/E ratio for the next fiscal year is 20.70. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.80 while its Price-to-Book (P/B) ratio in mrq is 5.13. Its current Enterprise Value per Revenue stands at 4.236 whereas that against EBITDA is 375.17.
Stock Price History:
The Beta on a monthly basis for KNSA is 0.20, which has changed by 0.33177936 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, KNSA has reached a high of $34.55, while it has fallen to a 52-week low of $17.82. The 50-Day Moving Average of the stock is 12.61%, while the 200-Day Moving Average is calculated to be 40.48%.
Shares Statistics:
KNSA traded an average of 775.09K shares per day over the past three months and 378460 shares per day over the past ten days. A total of 43.40M shares are outstanding, with a floating share count of 41.57M. Insiders hold about 43.90% of the company’s shares, while institutions hold 54.20% stake in the company. Shares short for KNSA as of 1755216000 were 2092794 with a Short Ratio of 2.70, compared to 1752537600 on 2533519. Therefore, it implies a Short% of Shares Outstanding of 2092794 and a Short% of Float of 5.2199997.
Earnings Estimates
The market rating of Kiniksa Pharmaceuticals International Plc (KNSA) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.43, with high estimates of $0.6 and low estimates of $0.31.
Analysts are recommending an EPS of between $1.78 and $0.94 for the fiscal current year, implying an average EPS of $1.24. EPS for the following year is $1.78, with 5.0 analysts recommending between $2.91 and $1.11.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $169.3M to a low estimate of $164.79M. As of the current estimate, Kiniksa Pharmaceuticals International Plc’s year-ago sales were $112.21MFor the next quarter, 6 analysts are estimating revenue of $176.31M. There is a high estimate of $181.5M for the next quarter, whereas the lowest estimate is $172M.
A total of 6 analysts have provided revenue estimates for KNSA’s current fiscal year. The highest revenue estimate was $645.4M, while the lowest revenue estimate was $633M, resulting in an average revenue estimate of $637.6M. In the same quarter a year ago, actual revenue was $423.24MBased on 6 analysts’ estimates, the company’s revenue will be $775.5M in the next fiscal year. The high estimate is $840.59M and the low estimate is $732M.
